Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chemoprophylaxis for HIV Prevention in Men

Next Previous
Trial Profile

Chemoprophylaxis for HIV Prevention in Men

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
  • Indications Herpes simplex virus type 2 infections; HIV infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms iPrEX

    • Most Recent Events

    • 26 Apr 2022 Results of a pooled participant-level data analysis ((iPrEx, VOICE and Partners PrEP studies) characterizing HIV-preventive, plasma tenofovir concentrations published in the Clinical Infectious Diseases
    • 11 Aug 2020 According to a Gilead Sciences media release, the China National Medical Products Administration (NMPA) has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg,FTC/TDF).The approval of Truvada for PrEP was supported by data from two randomized, double-blind, placebo-controlled trials known as the Pre-Exposure Prophylaxis Initiative (iPrEx) and Partners PrEP.
    • 03 Feb 2018 Results (n=498) assessing effects of TDF/FTC on lipids and body composition in participants in a blinded placebo controlled iPrEP trial, were published in the Clinical Infectious Diseases.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top